Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Biologics in Polymyositis and Dermatomyositis-Associated Interstitial Lung Disease

Author(s): Yuechi Sun, Yan He, Yuan Liu and Guixiu Shi

Volume 15, Issue 6, 2014

Page: [521 - 524] Pages: 4

DOI: 10.2174/138920101506140910145940

Price: $65

Abstract

Interstitial lung disease (ILD) is one of the most common complications of polymyositis (PM) and dermatomyositis (DM). It is always progressive and does not respond to conventional immunosuppressive agent treatment. Biologics are commonly used in treatment of rheumatic diseases. They are also used in polymyositis and dermatomyositis associated interstitial lung disease. This review will focus on the updated use of biologics in PM/DM-ILD.

Keywords: Biologics, dermatomyositis, interstitial lung disease, polymyositis.


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy